Rubric Capital Management (New York)’s Amneal Pharmaceuticals AMRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$137M	Sell	11,037,589 -1,297,352	-11%	-$17.4M	1.45%	18
2025 Q4	$155M	Hold	12,334,941	–	–	1.86%	14
2025 Q3	$123M	Buy	12,334,941 +624,609	+5%	+$5.61M	1.39%	16
2025 Q2	$94.7M	Buy	11,710,332 +974,355	+9%	+$7.35M	1.43%	21
2025 Q1	$90M	Buy	10,735,977 +14,199	+0.1%	+$119K	1.61%	18
2024 Q4	$84.9M	Hold	10,721,778	–	–	1.09%	18
2024 Q3	$89.2M	Hold	10,721,778	–	–	1.45%	14
2024 Q2	$68.1M	Buy	10,721,778 +1,179,830	+12%	+$7.49M	1.79%	18
2024 Q1	$57.8M	Buy	9,541,948 +1,541,948	+19%	+$8.7M	1.71%	22
2023 Q4	$48.6M	Buy	8,000,000 +3,975,500	+99%	+$17.7M	1.01%	24
2023 Q3	$17M	Buy	4,024,500 +1,423,121	+55%	+$5.31M	0.64%	39
2023 Q2	$8.06M	Buy	+2,601,379	New	+$5.54M	0.34%	50

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Rubric Capital Management (New York)'s AMRX Position: Q1 2026 in Review

Rubric Capital Management (New York) reduced its Amneal Pharmaceuticals (AMRX) stake by 11% in Q1 2026, selling an estimated $17.4M and leaving 11,037,589 shares worth $137M. The position accounts for 1.45% of the portfolio, ranked #18.

Rubric Capital Management (New York) first reported a position in AMRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $155M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Rubric Capital Management (New York) held 11,037,589 shares of Amneal Pharmaceuticals worth $137M as of Q1 2026.
Rubric Capital Management (New York) sold 1,297,352 Amneal Pharmaceuticals shares in Q1 2026, an estimated $17.4M.
Amneal Pharmaceuticals made up 1.45% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #18 holding.
Rubric Capital Management (New York) first reported a position in Amneal Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Rubric Capital Management (New York)'s Amneal Pharmaceuticals position peaked at $155M in Q4 2025.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.